A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes

被引:0
|
作者
Hong-Xiang Liu
Luca Cartegni
Michael Q. Zhang
Adrian R. Krainer
机构
[1] Cold Spring Harbor Laboratory,
[2] Xencor Inc.,undefined
来源
Nature Genetics | 2001年 / 27卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Point mutations can generate defective and sometimes harmful proteins. The nonsense-mediated mRNA decay (NMD) pathway minimizes the potential damage caused by nonsense mutations1,2,3,4. In-frame nonsense codons located at a minimum distance upstream of the last exon-exon junction are recognized as premature termination codons (PTCs), targeting the mRNA for degradation. Some nonsense mutations cause skipping of one or more exons, presumably during pre-mRNA splicing in the nucleus; this phenomenon is termed nonsense-mediated altered splicing (NAS), and its underlying mechanism is unclear1,2,5,6. By analyzing NAS in BRCA1, we show here that inappropriate exon skipping can be reproduced in vitro, and results from disruption of a splicing enhancer in the coding sequence. Enhancers can be disrupted by single nonsense, missense and translationally silent point mutations, without recognition of an open reading frame as such. These results argue against a nuclear reading-frame scanning mechanism for NAS. Coding-region single-nucleotide polymorphisms7 (cSNPs) within exonic splicing enhancers or silencers may affect the patterns or efficiency of mRNA splicing, which may in turn cause phenotypic variability and variable penetrance of mutations elsewhere in a gene.
引用
收藏
页码:55 / 58
页数:3
相关论文
共 50 条
  • [31] A screening assay for BRCA1 and BRCA2 mutations based on nonsense mediated decay
    Griffin, Helen
    Brown, R.
    Santibanez-Koref, M.
    Burn, J.
    Curtis, A.
    JOURNAL OF MEDICAL GENETICS, 2009, 46 : S66 - S66
  • [32] BRCA1 mutations
    DiCioccio, RA
    Werness, BA
    Piver, MS
    GENES CHROMOSOMES & CANCER, 2003, 37 (02): : 222 - 222
  • [33] Functional Restoration of BRCA1 Nonsense Mutations by Aminoglycoside-Induced Readthrough
    Abreu, Renata B. V.
    Gomes, Thiago T.
    Nepomuceno, Thales C.
    Li, Xueli
    Fuchshuber-Moraes, Mateus
    De Gregoriis, Giuliana
    Suarez-Kurtz, Guilherme
    Monteiro, Alvaro N. A.
    Carvalho, Marcelo A.
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [34] Prediction of Single-Nucleotide Substitutions That Result in Exon Skipping: Identification of a Splicing Silencer in BRCA1 Exon 6
    Raponi, Michela
    Kralovicova, Jana
    Copson, Ellen
    Divina, Petr
    Eccles, Diana
    Johnson, Peter
    Baralle, Diana
    Vorechovsky, Igor
    HUMAN MUTATION, 2011, 32 (04) : 436 - 444
  • [35] Functional differences among BRCA1 missense mutations in the control of centrosome duplication
    Z Kais
    N Chiba
    C Ishioka
    J D Parvin
    Oncogene, 2012, 31 : 799 - 804
  • [36] Mutations of the BRCA1 and BRCA2 genes and the possibilities for predictive testing
    Gayther, SA
    Ponder, BAJ
    MOLECULAR MEDICINE TODAY, 1997, 3 (04): : 168 - 174
  • [37] Prevalence of BRCA1 and BRCA 2 and other mutations in Chilean population.
    Selman, Carolina
    Hurtado, Mabel
    Chahuan, Badir
    Mella, Fabiola
    Marsiglia, Hugo
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [38] Functional differences among BRCA1 missense mutations in the control of centrosome duplication
    Kais, Z.
    Chiba, N.
    Ishioka, C.
    Parvin, J. D.
    ONCOGENE, 2012, 31 (06) : 799 - 804
  • [39] Testing Ashkenazi JewishWomen for Mutations Predisposing to Breast Cancer in Genes Other Than BRCA1 and BRCA2
    Narod, Steven
    Sopik, Victoria
    Cybulski, Cezary
    JAMA ONCOLOGY, 2018, 4 (07) : 1012 - 1012
  • [40] BRCA1 methylation and BRCA1 mutations in ovarian cancer
    Bol, Guus Martinus
    van Diest, Paul Joannes
    GYNECOLOGIC ONCOLOGY, 2011, 122 (02) : 459 - 459